ttphTetraphase Pharmaceuticals Inc (NASDAQ: TTPH) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the presentation of data from two Phase 3 clinical trials. Of course, the data was positive, exciting investors and sending the stock on a run for the top. Today, we’ll talk about:
- The data presentation;
- what we’re seeing from TTPH as a result; and
- what we’ll be watching for ahead.
TTPH Announces Data Presentation
As mentioned above, Tetraphase Pharmaceuticals is having an incredibly strong start to the trading session this morning after announcing the presentation of data. In a press release issued early this morning, TTPH said that data from a pooled analysis of two Phase 3 clinical studies of XERAVA in complicated intra-abdominal infections and a Phase 1 multiple-ascending dose study for its candidate, TP-6076 continue to be positive. In the release, the company said that the data were presented at the Infectious Disease Society of America’s (IDSA) Infectious Disease Week 2018.
In a statement, Guy Macdonald, President and CEO at TTPH, had the following to offer:
The data presented at IDWeek demonstrate high clinical cure rates and microbiological eradication with XERAVA among patients with cIAI and concurrent bacteremia… These data confirm the efficacy of XERAVA in a subgroup of cIAI patients who may be at higher risk for poor outcomes, and this new analysis comes at an exciting time as we make final preparations for the commercial launch of XERAVA in the coming weeks.
We are also encouraged by the positive safety, tolerability and pharmacokinetic data from the multiple-ascending dose Phase 1 study evaluating a seven-day dosing regimen for intravenous (IV) TP-6076. We plan to advance TP-6076 to a bronchopulmonary disposition study beginning in the first quarter of 2019 to confirm appropriate therapeutic levels of TP-6076 in the lungs to treat infections caused by Acinetobacter baumannii and other MDR pathogens. In previously completed in vitro testing, TP-6076 MIC90 values were as much as 64-fold lower than those for tigecycline against MDR Gram-negative pathogens, including Acinetobacter baumannii, suggesting that TP-6076 could be a potent treatment for these difficult-to-treat bacteria. We are enthusiastic about the potential for TP-6076 and the future of this program.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Tetraphase Pharmaceuticals, the news proved to be overwhelmingly positive. After all, the company released strong data relating to two of its pipeline candidates, taking these candidates one step closer to approval. So, it comes as no surprise that excited investors are sending the stock screaming for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:59), TTPH is trading at $2.75 per share after a gain of $0.18 per share or 7.00% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on TTPH. In particular, we’re interested in following the continued development of the company’s robust pipeline as the data continues to show promise. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!